Inex Innovate of Singapore plans to launch a PCR-based endometrial cancer detection test this summer, following interim results from a clinical study with researchers at the Chinese University of Hong Kong that were presented here at the Association of Molecular Pathology 2023 Europe Congress this week.

Seegene Inc. (KQ096530), a leading South Korean company which provides a total solution for PCR molecular diagnostics, announced an agreement with Werfen, a worldwide leader in Specialized Diagnostics, to advance discussions on the expansion of its current collaboration for the Spanish and Portuguese marketplaces through Seegene's OneSystem™ Business.

Boulder, Colorado-based Transformative Biotech announced on Thursday that it has acquired extraction-free, direct-to-PCR technologies from Summit Biolabs for undisclosed terms.

Following the announcement by China’s foreign ministry that PCR test results will no longer be required for all inbound travelers from April 29 onwards, the highly anticipated CACLP 2023 has entered its final countdown with less than one month to go.

China's foreign ministry said on Tuesday that all inbound travellers will only need to show COVID-19 antigen tests result taken within 48 hours before boarding flights starting April 29, dropping the PCR test requirement.

Curative Inc., a leading health services company that recently launched a new health plan out of Texas, announces the spin-off of Sensible Diagnostics, whose aim is to commercialize their groundbreaking point-of-care PCR testing platform.

OpGen announced on Tuesday that it has entered into a distribution partnership for its Unyvero A50 system and in vitro diagnostic tests with Fisher Healthcare, a division of Thermo Fisher Scientific.

The Berlin, Germany-based firm developed an assay for Marburg virus on its Minoo portable isothermal molecular diagnostic system.

Stilla Technologies and Atila BioSystems said on Thursday that they will codevelop digital PCR kits for cancer liquid biopsy applications.

Todos Medical said on Tuesday that it has signed a letter of intent with Acumen Diagnostics of Singapore under which its Provista Diagnostics subsidiary will offer Acumen's AcuSept sepsis test in the US.